A new study published in Nature Communications by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust reveals promising results for a novel immunotherapy treatment targeting melanoma. This aggressive form of skin cancer has a poor prognosis for half of patients within five years of diagnosis, and many current immunotherapies do not work for all patients. The new treatment utilizes an IgE antibody specifically designed to target immune responses towards melanoma cells, slowing cancer growth in mice and activating the immune system to fight cancer. Epsilogen Ltd owns rights to this new antibody and a previously developed IgE antibody for ovarian cancer, with results expected in 2023. This breakthrough opens up new possibilities for effective cancer treatment and a new frontier in the battle against cancer.
